Authors: Kaibalya Ranjan Dash Lalit Kumar Meher P K Hui S K Behera S N Nayak
Publish Date: 2014/09/28
Volume: 31, Issue: 2, Pages: 247-250
Abstract
Zidovudine AZT a nucleoside reverse transcriptase inhibitor was the first breakthrough in AIDS therapy in 1990This study was conducted with an aim to determine prevalence of AZT induced anaemia in HIV infected patients initiated on AZT containing anti retroviral therapyART regimen and also to find out any risk factor for causing AZT induced anaemia Study was carried out in ART centre MKCG MCH Berhampur between Jan 2009 and Dec 2011 HIV infected patients registered at ART centre were treated according to National AIDS Control Organisation NACO guidelines Patients n = 1221 with Hb 8 gm/dl were prescribed AZT based ART regimen Patients having anaemia 8 gm/dl were excluded from the study Correlation of baseline characteristics age sex weight Hb level CD4 count World Health Organization WHO clinical stage with risk of developing anaemia was also calculated 178 146 patients on AZT regimen developed anaemia Patients with low CD4 count were more prone to develop severe anaemia Age sex weight WHO clinical stage had no relation with development of anaemia Incidence of AZT induced anaemia was very high and patients having low CD4 count were more susceptible to develop anaemia
Keywords: